Michael Cherny
Stock Analyst at B of A Securities
(5.00)
# 5
Out of 4,868 analysts
111
Total ratings
55.42%
Success rate
141.25%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAH Cardinal Health | Maintains: Buy | $165 → $170 | $165.40 | +2.78% | 12 | Jun 10, 2025 | |
| BOLD Boundless Bio | Downgrades: Market Perform | $15 → $3 | $1.05 | +185.71% | 2 | May 28, 2025 | |
| MCK McKesson | Maintains: Buy | $755 → $800 | $728.91 | +9.75% | 13 | May 9, 2025 | |
| NVST Envista Holdings | Maintains: Buy | $26 → $23 | $18.61 | +23.59% | 11 | Apr 29, 2025 | |
| MEDP Medpace Holdings | Initiates: Market Perform | $330 | $302.69 | +9.02% | 1 | Mar 24, 2025 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $24 → $40 | $61.07 | -34.50% | 10 | Feb 25, 2025 | |
| CVS CVS Health | Upgrades: Outperform | $55 → $75 | $66.84 | +12.21% | 11 | Feb 13, 2025 | |
| PGNY Progyny | Maintains: Buy | $21 → $25 | $21.65 | +15.47% | 10 | Feb 11, 2025 | |
| DOCS Doximity | Upgrades: Outperform | $60 → $90 | $57.04 | +57.78% | 2 | Feb 7, 2025 | |
| ALGN Align Technology | Upgrades: Outperform | $235 → $280 | $180.01 | +55.55% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $135 → $174 | $179.78 | -3.22% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $71.13 | +18.09% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $154.61 | +60.40% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $143.58 | +77.60% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $15.40 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $296.75 | -7.33% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $23 → $22 | $11.39 | +93.15% | 2 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $261.39 | -0.53% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $23 | $22.26 | +1.08% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $4.49 | +78.17% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $19 | $10.58 | +79.67% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $7.01 | +142.51% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $5.63 | +832.50% | 2 | Jan 5, 2022 |
Cardinal Health
Jun 10, 2025
Maintains: Buy
Price Target: $165 → $170
Current: $165.40
Upside: +2.78%
Boundless Bio
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.05
Upside: +185.71%
McKesson
May 9, 2025
Maintains: Buy
Price Target: $755 → $800
Current: $728.91
Upside: +9.75%
Envista Holdings
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $18.61
Upside: +23.59%
Medpace Holdings
Mar 24, 2025
Initiates: Market Perform
Price Target: $330
Current: $302.69
Upside: +9.02%
Hims & Hers Health
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $61.07
Upside: -34.50%
CVS Health
Feb 13, 2025
Upgrades: Outperform
Price Target: $55 → $75
Current: $66.84
Upside: +12.21%
Progyny
Feb 11, 2025
Maintains: Buy
Price Target: $21 → $25
Current: $21.65
Upside: +15.47%
Doximity
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $57.04
Upside: +57.78%
Align Technology
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $180.01
Upside: +55.55%
Jan 6, 2025
Upgrades: Outperform
Price Target: $135 → $174
Current: $179.78
Upside: -3.22%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $71.13
Upside: +18.09%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $154.61
Upside: +60.40%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $143.58
Upside: +77.60%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $15.40
Upside: -
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $296.75
Upside: -7.33%
Mar 18, 2024
Maintains: Market Perform
Price Target: $23 → $22
Current: $11.39
Upside: +93.15%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $261.39
Upside: -0.53%
Feb 26, 2024
Initiates: Market Perform
Price Target: $23
Current: $22.26
Upside: +1.08%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $4.49
Upside: +78.17%
Feb 26, 2024
Initiates: Market Perform
Price Target: $19
Current: $10.58
Upside: +79.67%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $7.01
Upside: +142.51%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $5.63
Upside: +832.50%